Active Pharmaceutical Ingredients

PRODUCTS

API’s Category Specifications Regulatory Status
Atenolol Anti-Hypertensive IP/BP/EP/USP CEP, EU GMP,USDMF, CADIFA Filed
Amlodipine Besylate Anti-Hypertensive IP/BP/EP/USP DMF Available, CADIFA Filed, CEP is available
Metoprolol Succinate Anti-Hypertensive IP/BP/EP/USP USDMF filed
Metoprolol Tartrate Anti-Hypertensive IP/BP/EP/USP  USDMF filed
Roxithromycin Macrolides IP/BP/EP CEP
Azithromycin Macrolides IP/BP/EP/USP CEP, USDMF filed, CADIFA Filed
Clarithromycin Granules 27.5% Macrolides In-House DMF Available
Clarithromycin Granules 33% Macrolides In-House DMF Available
Clarithromycin Granules 43% Macrolides In-House DMF Available
Pregabalin Neuromodulator IP/EP/USP CEP, USDMF filed, CADIFA Filed
Ceftriaxone Sodium Sterile Cephalosporins IP/BP/EP/USP DMF Available
Cefotaxime Sodium Sterile Cephalosporins IP/BP/EP/USP DMF Available
Cefepime (with L-Arginine) for Injection Sterile Cephalosporins IP/USP
Meropenem (with Sodium Carbonate) for Injection Carbapenems IP/USP DMF Available
Doripenem Carbapenems JP/In-House DMF Available
Biapenem Carbapenems In-House DMF Available
Ertapenem Carbapenems In-House DMF Under Compilation
Faropenem Carbapenems JP/In-House DMF Available
Lymecycline Anti-Acne,
Anti-Infective
EP DMF Available, CEP is available
Nitroxoline Antibiotic (Urological) In-House DMF Available
Ticagrelor Anti-Thrombotic IP/EP/In-House DMF Available
Rivaroxaban Anti-Thrombotic EP/USP/In-House DMF Under Compilation,CEP is available
Apixaban Anti-Thrombotic In-House DMF Under Compilation
Edoxaban Tosylate Anti-Thrombotic In-House DMF Under Compilation
Empagliflozin Anti-Diabetic In-House DMF Available
Dapagliflozin Propanediol Monohydrate Anti-Diabetic In-House DMF Under Compilation
Montelukast Sodium Anti-Asthamatic IP/EP/USP DMF Under Compilation
Rosuvastatin Calcium Lipid-Lowering agent IP/EP/USP DMF Under Compilation
Tebipenem Carbapenems In-House  DMF Available

PELLETS

Pellets Category
Duloxetine Pellets 17%, 21.5% Anti-Depressent
Venlafaxine Pellets 33% Anti-Depressent
Dexlansoprazole Pellets 20%, 23% Proton Pump Inhibitor

PRODUCTS UNDER DEVELOPMENT

API’s Category R&D Sample availability R&D Tech pack availability Specifications
Canagliflozin Hemihydrate Anti-Diabetic Available Available In-House
Imipenem (Non-Sterile) Carbapenems Available Available In-House
Lacosamide Anti-convulsants Available Available EP/USP
Buspirone Hydrochloride Anti-Anxiety Agent Available Oct 2024 IP/EP/USP
Macitentan Pulmonary Arterial Hypertension Available Sep 2024 In-House
Riociguat Pulmonary Arterial Hypertension Available Sep 2024 EP/USP
Vericiguat Pulmonary Arterial Hypertension Oct 2024 Jan 2025 In-house
Ertugliflozin L-pyroglutamic acid Anti-Diabetic Available Jan 2025 In-House
Imipenem Cilastatin Sterile
Ivacaftor Cystic fibrosis
Mirogabalin Neuropathic Pain

PRODUCTS IN PIPELINE

API Therapeutic Category
Atogepant Anti-migraine
Avatrombopag Platelet enhancing drug
Bempedoic Acid Anti-hypertensive/Cardiovascular
Brivaracetam Anti-epileptic Neuromodulator
Finerenone Cardiovascular Nephrology
Upadacitinib Rheumatoid Arthritis
Vibegron Overactive Bladder Renal Hypertension

NOTE

  • Products will not be offered for sale in countries where valid Patents are in force.
  • It is the responsibility of the buyer to comply with the above.

For more information on API’s, send an e-mail to: api@kopran.com